Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / P [0.03%]
贝伐单抗联合FOLFIRI作为2006年不可切除的转移性结直肠癌初治患者一线治疗的常规实践评价：聚焦可切除患者和老年肿瘤患者：Brittany和Pays de la Loire地区肿瘤观察中心的AVASTIN OUEST队列研究
J P Metges,M A Lebot,R Faroux et al.
J P Metges et al.
Background: In 2006, bevacizumab, a targeted therapy agent was combined with FOLFIRI for the firstline treatment of patients with unresectable metastatic colorectal cancer. ...